The cell ganglioside composition reportedly affects the localisation of DR4 and DR5 into lipid rafts in B lymphoblastoid human cells [189]; therefore, it could be hypothesised that modifications concerning ganglioside metabolism could induce the exclusion of DR4 and DR5 from lipid rafts and, thus, cause the highly variable response of cancer cells to apoptosis during TRAIL treatments. Here, TNFRSF10B is linked to cancer.